- Researchers across the field, from Duke University to Mayo Clinic, are increasingly focused on restoring damaged cartilage rather than simply managing the symptoms associated with its loss.
- Regentis Biomaterials’ GelrinC is designed to support the body’s natural cartilage-regeneration process through a gradual, controlled repair environment.
- Early clinical data has provided encouraging evidence for GelrinC, which already has approval in Europe, while an FDA-authorized pivotal trial is advancing its development toward potential U.S. approval.
A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly, nearly a half-million Americans end up with knee cartilage damage each year as a result of long-term wear and tear and every-day accidents. For decades, many available treatments have focused on managing pain and restoring functions rather than actually replacing damaged cartilage with healthy tissue. Regentis Biomaterials (NYSE American: RGNT) is pursuing a different approach with GelrinC, an off-the-shelf hydrogel implant designed to support the regeneration of cartilage within the damaged area.
In brief
Regentis Biomaterials says GelrinC, an off-the-shelf hydrogel implant, is intended to support cartilage regeneration in damaged areas of the knee. The company describes the product as creating a gradual, controlled environment for repair and says early clinical data has provided encouraging evidence. GelrinC has approval in Europe, according to the release, and an FDA-authorized pivotal trial is underway as the company pursues potential U.S. approval. The release says nearly a half-million Americans experience knee cartilage damage annually due to wear and tear or accidents. It also notes that cartilage has limited blood supply, which can make substantial injuries difficult to heal. The announcement discusses cartilage-repair research at Duke University and Mayo Clinic, but provides no further trial details or clinical data in the supplied text.
Key takeaways
- GelrinC is an off-the-shelf hydrogel implant intended to support cartilage regeneration in damaged knee areas.
- The company says GelrinC has approval in Europe and an FDA-authorized pivotal trial is advancing.
- The release cites nearly a half-million Americans experiencing knee cartilage damage each year.
- The supplied text provides no detailed trial results or clinical data.
Cartilage is very difficult for the body to repair on its own. Unlike many other tissues, it has limited blood supply, which can make significant injuries difficult to heal and leave patients vulnerable to persistent pain, stiffness and progressive joint degeneration. Researchers across the field, including teams at Duke University and the Mayo Clinic, have been exploring ways to encourage…
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid investor awareness and marketing engagement.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]
Questions around this news
What is GelrinC designed to do?
GelrinC is an off-the-shelf hydrogel implant intended for use in a damaged area of knee cartilage. Regentis Biomaterials says it is designed to create a gradual, controlled repair environment that supports the body’s natural cartilage-regeneration process. The release describes it as an approach focused on restoring cartilage rather than only managing symptoms.
What is GelrinC’s regulatory status?
The release says GelrinC has approval in Europe. It also reports that an FDA-authorized pivotal trial is underway as the product advances toward potential U.S. approval. It does not provide further details about the trial’s design, enrollment, timing or results, or identify a date when a U.S. regulatory decision might occur.
Why can knee cartilage injuries be difficult to heal?
Cartilage has a limited blood supply, which can restrict the body’s ability to repair significant damage. A substantial injury may therefore persist and contribute to symptoms such as pain and stiffness. The release also notes that damaged cartilage can be associated with progressive joint degeneration, although the effects and course of an injury vary.
What does a pivotal clinical trial mean?
A pivotal clinical trial is a major study intended to provide evidence about a medical product’s safety and effectiveness for regulatory review. Its design depends on the product and the questions regulators need answered. A trial’s authorization to proceed does not itself mean the product has been approved for use in that market.
SEC filings
Earlier from Regentis Biomaterials Ltd.
- Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC
- Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks
- Regentis Biomaterials (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market
- Regentis Biomaterials (NYSE American: RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C
- Regentis Biomaterials (NYSE American: RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
